Taylor J. Linaburg

Taylor J. Linaburg

Auto-generated profile, based on publicly available information

Taylor J. Linaburg

Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2024 in Infectious Disease Clinics of North America
Verified
Journal Article
Closed access
TLTaylor J. Linaburg
Taylor J. Linaburg
KHKristin M. Hammersmith
Kristin M. Hammersmith

1 January 2024 in Case Reports in Ophthalmology
Verified
Journal Article
Open access
PDF file
TLTaylor J. Linaburg
Taylor J. Linaburg
JAJaviera Araya
Javiera Araya
CBCésar A. Briceño
César A. Briceño
Introduction: Maxillary ameloblastoma is a rare, slow-growing odontogenic tumor that can recur after surgical excision, be locally aggressive, and rarely develop systemic metastases. We describe the course and management of a patient with recurrent maxillary ameloblastoma with orbital invasion and systemic metastases, the fourth case of its kind to be described in the literature. Case Presentation: A 50-year-old female presented with left hyperglobus. A diagnosis of maxillary ameloblastoma was made based on biopsy and neuroimaging with MRI and CT. Surgical management included partial maxillectomy with orbital floor reconstruction, given the orbital invasion. Three years later, left hyperglobus recurred, and the patient was found to have orbital recurrence and lung metastases on PET imaging. The lung and orbital lesions have responded well to chemoradiation therapy without surgical intervention. Conclusion: Maxillary ameloblastoma is a rare tumor that typically arises from odontogenic tissues. Though considered benign, they can recur and in the case of our patient, metastasize. Complete surgical excision with wide surgical margins is associated with a shorter average time to recurrence and a lower incidence of metastasis. Cases of metastasis are managed with chemotherapy with or without adjuvant radiotherapy. Precision medicine may play a role in managing this entity in the future, given the discovery of differing profiles of maxillary ameloblastoma compared to mandibular. Ophthalmologists should be aware of this tumor as it can invade the orbit, resulting in significant ocular morbidity and mortality.

1 March 2025 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
AGAngela S Gupta
Angela S Gupta
TLTaylor J Linaburg
Taylor J Linaburg
EIEmma Iacobucci
Emma Iacobucci
PAPatrick Augello
Patrick Augello
VQVivian L Qin
Vivian L Qin
MMMina Massaro
Mina Massaro
Purpose: We evaluated the efficacy of varenicline solution nasal spray (VNS) in treating dry eye disease (DED) associated with moderate to severe Sjogren’s disease and analyzed tear film cytokine levels of patients with DED and Sjogren’s disease before and after VNS use. Methods: This was a pilot study involving a single-center, single-arm investigator-initiated trial. Patients with moderate to severe Sjogren’s disease were given VNS 0.03 mg twice daily for 28 days. Patients were assessed on day 0 before VNS use, day 14 and day 28. Clinical exam findings, symptomatology as measured by the eye dryness score, and tear cytokines were assessed at baseline and day 28. Results: Thirty-nine subjects were included. Between day 0 and day 28, there was a statistically significant improvement in the eye dryness score (p = 0.01), corneal staining (p < 0.001), and conjunctival staining (p = 0.04). There was a statistically significant increase in tear secretion by unanesthetized Schirmer’s in subjects with a baseline Schirmer’s ≤ 5 mm (n = 35 eyes, p = 0.02) and a non-statistically significant increase in tear secretion in subjects with a baseline Schirmer’s of 6– 10 mm (n = 16 eyes, p = 0.79). There was a statistically significant decrease in tear film cytokine concentration of IFNγ (p = 0.0003), IL-12p70 (p < 0.0001), IL-17a (p = 0.004), IL-1β (p = 0.007), IL-2 (p < 0.0001), IL-4 (p = 0.01), and TNF-α (p = 0.02), and no significant change in IL-6 (p = 0.56) and IL-10 (p = 0.18). Conclusion: Our findings add to existing evidence that VNS improves subjective dry eye symptoms, corneal and conjunctival staining, and tear secretion in a subset of tear-deficient patients, while providing new evidence that VNS reduces concentration of pro-inflammatory cytokines in the tear film. Clinical Trial Registration Number: NCT05700422.

1 January 2025 in Arquivos Brasileiros de Oftalmologia
Verified
Journal Article
Open access
TLTaylor J. Linaburg
Taylor J. Linaburg
TPTejus Pradeep
Tejus Pradeep
BRBrian Rinelli
Brian Rinelli
YCYuanyuan Chen
Yuanyuan Chen
YCYineng Chen
Yineng Chen
MTMadhura Tamhankar
Madhura Tamhankar
This study evaluated rates of thyroid eye disease-related eyelid surgeries, strabismus surgeries, and orbital decompressions in active thyroid eye disease patients treated with teprotumumab compared to those who were not. In this single-center longitudinal study, we compared patients with active thyroid eye disease evaluated from 02/01/2017 to 01/31/2020 (pre-teprotumumab era) with those seen from 02/01/2020 to 04/30/2023 (teprotumumab era). Patients from the pre-teprotumumab era who received corticosteroids and/or orbital radiation were compared with those in the teprotumumab era treated with teprotumumab, with or without corticosteroids and/or orbital radiation. The primary outcomes were rates of orbital decompressions, strabismus surgery, and eyelid surgery among patients with at least 6 months of follow-up. Orbital decompressions involving two or more walls were classified as severe. Of 486 records reviewed, 106 patients had active thyroid eye disease. Among them, 33 were from the pre-teprotumumab era; 22 received corticosteroids and/or orbital radiation, and 11 received no treatment. Seventy three patients were from the teprotumumab era; 37 received teprotumumab (with or without corticosteroids and/or orbital radiation), 10 received corticosteroids and/or orbital radiation alone, and 26 received no treatment. Demographics were comparable between groups. Orbital decompression was performed in 11 of 44 eyes (25.0%) in the pre-teprotumumab era treated with corticosteroids and/or orbital radiation (8 one-wall, 3 ≥two-wall), compared to 3 of 74 eyes (4.1%) in the teprotumumab era treated with teprotumumab with or without corticosteroids and/or orbital radiation (all one-wall). The overall rate of orbital decompressions and the rate of ≥two-wall decompressions were significantly lower in the teprotumumab era (p=0.02 and p=0.0496, respectively). There was no significant difference in one-wall decompressions between era (p=0.07). Rates of strabismus surgeries (27.3% vs. 13.5%, p=0.19) and eyelid surgeries (22.7% vs. 21.6%, p=0.92) did not significantly differ between the era. In patients with active thyroid eye disease, treatment with teprotumumab was associated with a significantly lower rate and severity of orbital decompressions compared to treatment with corticosteroids and/or orbital radiation alone. However, the rates of strabismus and eyelid surgeries remained similar between groups.

5 February 2024 in Ophthalmic Plastic & Reconstructive Surgery
Verified
Journal Article
Closed access
TLTaylor J. Linaburg
Taylor J. Linaburg
GLGabriela Lahaie-Luna
Gabriela Lahaie-Luna
TPTejus Pradeep
Tejus Pradeep
TBTrisha Bhatti
Trisha Bhatti
WKWilliam Katowitz
William Katowitz
We describe the first case reported in ophthalmological literature of the surgical management of a 17-month-old boy with bilateral vision-threatening ptosis, tarsomegaly, ectropion, and euryblepharon secondary to suspected overgrowth syndrome. We elaborate on the major challenges associated with surgical management including the natural and asymmetric growth of oversized tissue, the high likelihood of scarring and formation of disorganized tissue, and risks of frequent intubation in these patients who may have lesions that compromise critical structures such as the airway. Ultimately, surgical intervention is encouraged primarily if vision or ocular health is threatened and secondarily to achieve good cosmesis.

9 May 2025 in Journal of American Association for Pediatric Ophthalmology and Strabismus
Verified
Journal Article
Closed access
TLTaylor J. Linaburg
Taylor J. Linaburg
GBGil Binenbaum
Gil Binenbaum
ABAdva Buzi
Adva Buzi
ASAlyssa Spiller
Alyssa Spiller
YYYinxi Yu
Yinxi Yu
WKWilliam R. Katowitz
William R. Katowitz